IPO
IPO filing, visualized

Regenlab USA Inc.

Blood-processing devices for regenerative medicine

RGNAS-1/A · Oct 27, 2026Price range set

Pricing expected any day (our estimate) · latest SEC filing Oct 28, 2026.

Pinch-zoom for details.

The offering

Price range
$6–$8
per share
Shares offered
2.50M
sold by the company
Raise at $7 midpoint
$17.5M
2,500,000 × $7, before fees
Net proceeds (company est.)
$15.5M
at $7 a share

What the company does

RegenLab makes devices that process a patient's own blood for regenerative medicine, such as platelet-rich plasma. Founded in Switzerland, it now has a U.S. holding company and sites in New Jersey, Paris and Monthey (Switzerland).

It holds over 70 granted patents.

Revenue

Fiscal year

Operating result

Fiscal year

Net result

Fiscal year

Who controls the votes

Insiders' voting power
87.66%

Share of voting power held by the founders or controlling holders after the offering, as stated in the filing.

Things to weigh

  • Loss-making: net loss of $1.24M in FY2025.
  • Insiders keep control: about 87.66% of the voting power after the offering.

The numbers

$FY2024FY2025YoY
Revenue48.4M49.2M+1.6%
Operating result3.48M675K−80.6%
Net result2.31M(1.24M)n/m

Values as filed, shortened (K = thousand, M = million, B = billion); losses in parentheses. Change columns compare each period with the same period a year earlier; a bigger loss shows as a negative change. Green is better for the company, red worse; n/m where the sign flips.

Risks

  1. Needs to keep regulatory approvals to sell its products.
  2. Sales depend on insurers and health systems paying for its treatments.
  3. New or competing technologies could take sales.
  4. Relies on relationships with doctors and on building its sales force.

In plain English, from the filing's risk factors.

Strategy

  1. Grow market share in musculoskeletal treatments.
  2. Launch its FDA-approved wound gel in the U.S.
  3. Expand in aesthetic medicine in Europe.
  4. Start clinical studies in women's health.

In plain English, from the filing's strategy section.

Source: Regenlab USA Inc.'s Form S-1/A, filed with the SEC on Oct 27, 2026 (preliminary prospectus). Figures are as filed; changes are worked out from them. Not investment advice.

10KDecoder10KDecoder.com

10KDecoder (10-K Decoder): decode SEC 10-K filings and IPO prospectuses into dashboards and infographics.